Browse by author
Lookup NU author(s): Dr Salman Razvi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
© 2022 Merck Healthcare KGaA. Published by Informa UK Limited, trading as Taylor & Francis Group. Lifelong treatment with levothyroxine (LT4) is the mainstay of management for individuals with hypothyroidism. Many hypothyroid patients start LT4 treatment at a low dose (e.g. 25–50 µg), especially the elderly, those with residual thyroid function, those with low body weight, and those with significant (especially cardiac) comorbidities. Almost half of patients on LT4 replacement therapy demonstrate either under- or over-treatment. Many LT4 preparations have relatively large intervals between tablet strengths at the lower end of their dose ranges (providing 25 µg, 50 µg, and 75 µg tablets), which may represent a barrier to achieving the optimum maintenance treatment for some patients. The availability of intermediate tablet strengths of LT4 in the 25–75 µg range may facilitate precise and effective dose titration of LT4 and may also enable convenient maintenance regimens based on a single LT4 tablet daily, to support adherence to therapy.
Author(s): Gottwald-Hostalek U, Razvi S
Publication type: Review
Publication status: Published
Journal: Current Medical Research and Opinion
Year: 2022
Pages: Epub ahead of print
Online publication date: 12/05/2022
Acceptance date: 25/04/2022
ISSN (print): 0300-7995
ISSN (electronic): 1473-4877
Publisher: Taylor and Francis Ltd.
URL: https://doi.org/10.1080/03007995.2022.2071059
DOI: 10.1080/03007995.2022.2071059
PubMed id: 35484983
